Annual Total Liabilities
$252.70 M
+$13.01 M+5.43%
December 31, 2023
Summary
- As of February 8, 2025, ARQT annual total liabilities is $252.70 million, with the most recent change of +$13.01 million (+5.43%) on December 31, 2023.
- During the last 3 years, ARQT annual total liabilities has risen by +$225.05 million (+813.98%).
- ARQT annual total liabilities is now at all-time high.
Performance
ARQT Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$280.71 M
+$22.38 M+8.66%
September 30, 2024
Summary
- As of February 8, 2025, ARQT quarterly total liabilities is $280.71 million, with the most recent change of +$22.38 million (+8.66%) on September 30, 2024.
- Over the past year, ARQT quarterly total liabilities has increased by +$34.47 million (+14.00%).
- ARQT quarterly total liabilities is now at all-time high.
Performance
ARQT Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
ARQT Total Liabilities Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +5.4% | +14.0% |
3 y3 years | +814.0% | +14.0% |
5 y5 years | +236.6% | +14.0% |
ARQT Total Liabilities Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +128.7% | at high | +167.1% |
5 y | 5-year | at high | +814.0% | at high | +2143.9% |
alltime | all time | at high | +2767.7% | at high | +2143.9% |
Arcutis Biotherapeutics Total Liabilities History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $280.71 M(+8.7%) |
Jun 2024 | - | $258.33 M(+1.9%) |
Mar 2024 | - | $253.60 M(+0.4%) |
Dec 2023 | $252.70 M(+5.4%) | $252.70 M(+2.6%) |
Sep 2023 | - | $246.24 M(+2.5%) |
Jun 2023 | - | $240.18 M(+0.2%) |
Mar 2023 | - | $239.73 M(+0.0%) |
Dec 2022 | $239.69 M(+117.0%) | $239.69 M(+0.7%) |
Sep 2022 | - | $238.14 M(+126.6%) |
Jun 2022 | - | $105.08 M(-4.8%) |
Mar 2022 | - | $110.34 M(-0.1%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2021 | $110.47 M(+299.6%) | $110.47 M(+360.1%) |
Sep 2021 | - | $24.01 M(+30.5%) |
Jun 2021 | - | $18.40 M(-9.9%) |
Mar 2021 | - | $20.42 M(-26.1%) |
Dec 2020 | $27.65 M(-83.9%) | $27.65 M(+10.8%) |
Sep 2020 | - | $24.94 M(+8.2%) |
Jun 2020 | - | $23.05 M(+84.2%) |
Mar 2020 | - | $12.51 M(-92.7%) |
Dec 2019 | $172.04 M(+129.1%) | $172.04 M(+111.7%) |
Sep 2019 | - | $81.25 M(+8.2%) |
Dec 2018 | $75.08 M(+752.1%) | $75.08 M |
Dec 2017 | $8.81 M | - |
FAQ
- What is Arcutis Biotherapeutics annual total liabilities?
- What is the all time high annual total liabilities for Arcutis Biotherapeutics?
- What is Arcutis Biotherapeutics annual total liabilities year-on-year change?
- What is Arcutis Biotherapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Arcutis Biotherapeutics?
- What is Arcutis Biotherapeutics quarterly total liabilities year-on-year change?
What is Arcutis Biotherapeutics annual total liabilities?
The current annual total liabilities of ARQT is $252.70 M
What is the all time high annual total liabilities for Arcutis Biotherapeutics?
Arcutis Biotherapeutics all-time high annual total liabilities is $252.70 M
What is Arcutis Biotherapeutics annual total liabilities year-on-year change?
Over the past year, ARQT annual total liabilities has changed by +$13.01 M (+5.43%)
What is Arcutis Biotherapeutics quarterly total liabilities?
The current quarterly total liabilities of ARQT is $280.71 M
What is the all time high quarterly total liabilities for Arcutis Biotherapeutics?
Arcutis Biotherapeutics all-time high quarterly total liabilities is $280.71 M
What is Arcutis Biotherapeutics quarterly total liabilities year-on-year change?
Over the past year, ARQT quarterly total liabilities has changed by +$34.47 M (+14.00%)